At Tethis we have built over the years what is truly, not just in words, a multidisciplinary team of highly trained and qualified individuals with very different backgrounds (from physics to biology, engineering, clinics, quality and finance). Most importantly, they have learned to speak the same language of product development, sharing the ultimate common goal to bring game changing diagnostic solutions to the market.
People
Board of Directors & Key Managers
Mario Zanone Poma
Honorary Chairman
Mario has a long managerial experience. Having been CEO and chairman of large companies such as Kalle Infotec (Hoechst Group), Telepiù, Mediocredito Italiano, Adv Board Cap Gemini Ernst & Young, Italy-China Chamber of Commerce. He is currently chairman of Wise, Agite! and CEI (energy)
Daniele Timothy Scarinci
Chairman
Daniele is Founder and Managing Partner at XGen Venture. He served Tethis as CEO for 2 years, and Genextra for 15 years as Investment Director investing in lifescience companies. Before that, he worked at Italian tlc operator Fastweb in the strategic planning and investor relations department, and previously as an equity analyst for an independent research firm in London.
Holger Neecke
PhD, MBA – Chief Executive Officer
Holger is a molecular biologist with 20+ years of experience in the pharma industry, specifically in business development. He served as Head of the TTO at the AIRC Institute of Molecular Oncology (IFOM) and previously as Business Development Director at Adare Pharmaceuticals, Ablynx, and MolMed.
Bastiaan van der Baan
MSc – Independent Director
Bas is CSO Lixte Biotechnology, a listed US pharma company developing innovative cancer therapies.
Previously, he served as Chief Clinical and Business Officer at oncology DX company Agendia, building up the global clinical and commercial infrastructure. Bas brings 25+ years of healthcare experience.
Miro Venturi
PhD, MSc – Independent Director
Miro is Partner at Archimed, a global PE organization, with HQs in France, and Board Member of Swiss DX companies Novigenix and Tivenix. Previously, he served as CBO at Foundation Medicine, a leader in oncology molecular diagnostics part of Roche, where he held positions in the Pharma and Diagnostics divisions.
Davide Turco
PhD, MBA – Non Exec Director
Davide is Co-Founder and Managing Director of Indaco Venture Partners SGR. Previously, he served as Venture Capital Manager in the Intesa Sanpaolo Group, where in 2007 he promoted the start-up of Venture Capital activities. He started his career in Private Equity, initially at Sige Investimenti and Mediocredito Lombardo, then as Senior Investment Manager at Intesa Sanpaolo.
Since January 2025 he is Chairman of Italian Tech Alliance, an association that promotes the innovation ecosystem in Italy.
Alvise Bonivento
Non Exec Director
Alvise is Investment Director at Indaco SGR and serves as board member in several portfolio companies. He worked as researcher in Silicon Valley and at the Electrical Engineering and Computer Science Department of University of California at Berkeley.
Carmelo Catalano
Board member
Carmelo serves as Chief Financial Officer of Fondazione Enea Tech e Biomedical, a shareholder of Tethis S.p.A. A Certified Public Accountant and Statutory Auditor, he is responsible within the Foundation for the Administration, Accounting and Tax area, as well as Finance, Planning, Budgeting and Control, and Facility Management and Treasury. He began his professional career at Rete Ferroviaria Italiana, where he held positions of responsibility across various AFC (Administration, Finance and Control) functions, gaining significant experience in M&A transactions and Strategic Planning. He joined the Foundation in July 2023. He is also a member of the Board of Directors of Health Triage S.p.A.
Gian Martino Franchi
Chief Technology Officer
Martino holds a M.Sc. in Physics.
He has managed projects concerning IVD devices, automation with liquid handling systems and nanomaterial systems. He is co-author of several patent applications.
Roberta Carbone
PhD – Chief Scientific Officer
Roberta has served as reasercher for 10 years at the Experimental Oncology Lab of the European Institute of Oncology (IEO) in Milan before joining Tethis. She is co-author of more than 30 peer reviewed publications in international journals and several patent applications.